Proactive Investors - Run By Investors For Investors

Elixinol Global attracts $40 million to accelerate international growth initiatives

The company is increasing the capacity of its hemp-derived cannabidiol production facility in the US.
hemp oil
Elixinol is awaiting a medicinal cannabis license in Australia

Elixinol Global Ltd (ASX:EXL) (OTCMKTS:ELLXF) has successfully completed a share placement to domestic and international institutional and sophisticated investors raising $40 million at $1.85 per share.

The group’s portfolio comprises three main divisions: Elixinol USA focused on dietary supplements; Hemp Foods Australia selling food products; and Elixinol Australia, the new start-up focused on medicinal cannabis.

The company listed on the ASX in January this year and raised about $20 million from an oversubscribed initial public offer.

Elixinol chief executive officer Paul Benhaim said: “The global cannabis market is growing at a rapid rate and Elixinol Global recognises the need to move quickly to leverage the opportunity around the business.

“This funding ensures we can seize the market opportunities in front of us, and in doing so, propel the business toward its next phase of growth.”

 

Elixinol will apply the funds towards increasing the capacity of its hemp-derived CBD (cannabidiol) production facility in the US to prepare for increasing levels of demand.

The company will also ramp up its sales force and marketing efforts in the US and Europe.

The new funding will also provide Elixinol with additional working capital to support its growth, pursue strategic investment opportunities and construct its Australian medicinal cannabis facility, upon receipt of a medicinal cannabis license from the Office of Drug Control.

Benhaim added: “We are grateful for the support from existing and new investors who participated in this capital raising in recognition of our world-class brand that continues to drive revenue growth and profitability for Elixinol Global.”

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full EXL profile View Profile

Elixinol Global Ltd Timeline

Related Articles

Cannabis leaf
November 19 2018
With the legalisation of recreational cannabis in Canada in October, and the US expected to follow suit, the company has its sights set on building up the very best in the industry
Laboratory testing
October 09 2018
Fifteen patients have been enrolled in the trial being carried out at Children’s Hospital of Philadelphia in the USA.
The R&D programme is intended to address the increasing prevalence of obesity and diabetes using smart siRNA
October 30 2018
The health sciences company noted that the plan was formulated at a recently held two-day intensive workshop which together leading scientific teams from the QIMR Berghofer Medical Research Institute in Brisbane and Murdoch University in Perth

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use